Stacey Chang-Douglass
Head of Health Economics and Director in Consulting
Stacey is Head of Health Economics and Director in Consulting at Clarivate.
Stacey has nearly 15 years’ experience in health economics and outcome research at consultancies and at NICE. She specialises in economic modelling to support HTA submissions, global model development and country adaptation and national guidelines across an extensive range of therapeutic areas.
Prior to joining Clarivate, Stacey held senior positions at different consultancies, as Principal Consultant at Parexel, Director in Health Economics at Lumanity and Research Scientist at Evidera, where she led multidisciplinary projects for economic modelling and evidence synthesis. She provided quality assurance for deliverables and technical guidance for the internal team and provided strategic insights to ensure a long-term partnership with the clients.
Stacey serves as a standing committee member at the Medical Technologies Advisory Committee at NICE since 2022. Stacey also serves as a reviewer of funding proposals and HTA reports for NIHR in the UK since 2015.
Stacey holds an MSc in International Health Policy from London School of Economics and a PhD in Health Sciences from the University of York, which focused on outcome measurements in economic evaluations.
Latest news
New Clarivate Report Reveals Mainland China as Emerging Global Biopharma Innovation Leader
Out-Licensing Deals Reach $50 Billion as Chinese Biopharma Innovators Drive Breakthrough Science LONDON, U.K. December 8, 2025 Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, in partnership…
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle London, U.K. — December 4, 2025 — Clarivate Plc…
Clarivate and the Chinese Academy of Sciences Release the 2025 Research Fronts Report
Annual report identifies 110 hot and 18 emerging Research Fronts London, U.K. December 3, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy…
